ImageneBio Reports $24.8 Million Net Loss in Q3 2025, Increases R&D Spending

ImageneBio, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company, which focuses on developing therapeutics for immunological and inflammatory diseases, recorded a net loss of $24.8 million for the third quarter, a substantial increase from a loss of $3.2 million in the same period last year. For the nine months ended September 30, 2025, the net loss totaled $38.4 million, compared to $31.8 million for the same period in 2024. The increase in losses is attributed to a rise in operating expenses, particularly in research and development, which surged to $15.6 million from $3.9 million year-over-year.

The company did not generate any license revenue in the third quarter of 2025, a decline from $3.5 million in the previous year. This drop is primarily due to the absence of new licensing agreements following the divestiture of its non-IMG-007 business assets to Miragene Inc. in July 2025. Operating expenses for the quarter reached $26.6 million, a 380% increase compared to $5.5 million in the prior year, driven largely by stock-based compensation and increased administrative costs associated with the company's transition to a public entity.

In terms of strategic developments, ImageneBio completed a merger with Legacy Inmagene on July 25, 2025, which was accounted for as a reverse recapitalization. This merger resulted in a significant increase in the company's cash position, with cash and cash equivalents rising to $103.2 million from $12.1 million at the end of 2024. The merger also included a PIPE financing that raised approximately $75 million, which is expected to support ongoing research and development activities, including the advancement of its lead product candidate, IMG-007.

Operationally, the company is focused on advancing IMG-007, a monoclonal antibody targeting the OX40 receptor, which is currently in a Phase 2b clinical trial for atopic dermatitis. The company plans to expand its clinical development to additional indications, including alopecia areata and asthma. As of September 30, 2025, ImageneBio had a total of 11.2 million shares of common stock outstanding, reflecting the impact of the merger and subsequent stock issuance.

Looking ahead, ImageneBio anticipates continued investment in its research and development pipeline, with expectations of incurring significant losses as it seeks regulatory approval for IMG-007 and potentially other product candidates. The company has indicated that it will require substantial additional funding to support its operations and development activities, and it plans to explore various financing options, including equity offerings and collaboration agreements, to ensure its financial stability moving forward.